Our group of academic and industry partners won a big MRC grant yesterday is led by George Freeman, the UK's Under Secretary of State for Life Science. Niche Science & Technology Ltd. is a part of the winning consortium. A group of businesses, health care providers, and universities has been given £4.8 million to invest in a new, innovative research project. The goal of the programme is to change how severe asthma is diagnosed and treated and to pave the way for the creation of new treatments. The United Kingdom Refractory Asthma Stratification scheme (RASP-UK) is a partnership between the MRC, Asthma UK, and a group of pharmaceutical companies. It is run by top clinical and academic experts from the UK, and the pharmaceutical companies are also giving £4.8 million to the scheme. Professor Liam Heaney of Queen's University Belfast is in charge of the project.
The goal of the project is to change how hospitalised patients with severe asthma are treated and give each patient a more customised care plan. Most people agree that the current "one size fits all" approach to treating asthma, which involves slowly increasing the amount of therapy even though patients still don't react, isn't working for people with severe asthma. Half of the stress on healthcare resources comes from the 20% of people with serious asthma who still can't get their symptoms under control even after trying all the treatments that are currently available.
Niche is an important part of how the consortium runs and manages the clinical studies for the projects. New ways to give treatments will be investigated by the programme. These new ways will be better suited to the specific needs of each patient. It will also investigate why some patients don't react to current treatments, which is very important, so that possible new drug treatments can be found.
The CEO of Niche Science and Technology Ltd., Dr. Tim Hardman, said today, "This is a very exciting research programme, and Niche is delighted to be asked to take part."
The funding is part of an MRC investment of £13.7 million in teams working on stratified medicine. This was announced by George Freeman, the UK Minister for Life Sciences. George Freeman said at the London Stock Exchange this morning (Thursday, January 29): "The UK is a world leader in the life sciences, and the sector is key to economic growth." Since we started our UK Strategy for Life Sciences in 2011, the industry has agreed to invest more than £3.5 billion in the UK. This is estimated to create more than 11,000 jobs.
The head of the MRC, Professor Sir John Savill, said, "The goal of stratified medicine is to give patients the best treatments by making sure that existing medicines are targeted at those who will benefit most and by speeding up the development of new therapies." To reach this goal, we need partnerships that use the different kinds of knowledge, skills, and dedication that come from patients, businesses, and universities. We're in a great position to be leaders in this field here in the UK because we have access to some of the best clinical tools and data in the world and do excellent research. This is making small, medium, and big businesses from all over the UK and the world want to work with us. The groups we help are eager to work with new partners, and we will be looking into other disease areas that could benefit from this method.
Visit the consortium website to learn more about the project and the consortium [1].
References
Concerns about readiness of the European Medicines Agency’s (EMA) Clinical Trials Information System persist as the.
Have you seen our latest Insider's Insight on Case Reports? Once a staple of medical journals,
When I was younger, the opening lines of the Beatle’s seminal ‘Sgt. Pepper’s Lonely Hearts Club Band’ resonated.
Frights create a happy Halloween by providing the thrill of fear in a controlled and safe environment, turning what.
Welcome to the seventh issue of the Refractory Asthma Stratification Programme (RASP-UK) newsletter
The proceedings of the Association for Human Pharmacology in the Pharmaceutical Industry (AHPPI)
It was encouraging to see so many partners at the 2017 General Assembly meeting last December
Investigator-Initiated Clinical Trials (IITs) are clinical studies led by academic researchers or clinicians
The clinical stage biotechnology company developing breakthrough therapies for patients suffering with cancer,
I am shamelessly referencing our Insider’s Insights (IIs) to Dr Who’s TARDIS – our latest edition
Investigator sites are very important to clinical studies because they make sure that new drugs are safe and work well.
The UK's world-class human challenge study gives us new information about SARS-CoV-2 cases that were mild in 36 healthy.
Experience at Niche has taught us that clinical study protocols are born in the white-hot fire
Advisory board meetings are often used to address perceived knowledge gaps and build consensus.
Every year, a huge amount of scientific data is released. It's out there, but how do you find it?
Rational Vaccines (RVx) announces MHRA Innovation Licensing and Access Pathway (ILAP) approval for their live attenuated.
The largest pharmaceutical companies not surprisingly rely on the largest contract research organizations
Get our latest news and publications
Sign up to our news letterResources
Social
Contact us
Address
Niche Science & Technology
Unit 26 Falstaff House
Bardolph Road
Richmond TW9 2LH
United Kingdom
